meningioma contraindacation to peptides peptide - PRRTmeningioma side effects Meningioma Contraindications to Peptides: Navigating Risks and Treatment Options

PRRTmeningioma Meningiomas, the most common primary brain tumors in adults, accounting for approximately a third of all intracranial neoplasms, can present complex treatment challenges. While surgery and radiotherapy remain primary interventions, systemic medical therapies are increasingly considered for treatment-refractory cases. Among these emerging treatments, peptide receptor radionuclide therapy (PRRT) has shown promise, particularly for advanced, recurrent, or progressive meningiomas. However, as with any medical intervention, understanding the contraindications and potential side effects associated with peptides is crucial for patient safety and treatment efficacy.Meningioma: A Review of Clinicopathological and ...

Peptide Receptor Radionuclide Therapy (PRRT) in Meningioma Treatment

PRRT is a targeted therapy that delivers high doses of radiation directly to tumor cells. This approach leverages the expression of somatostatin receptors (SSTRs) on many meningiomas, similar to their presence on neuroendocrine tumors.作者：C Marosi·被引用次数：1—These drugs may be more effective than imatinib as monotherapy againstmeningiomasbut also present a higher risk forside effects[77]. ▫ Other Drugs. There ... By using radiolabeled peptides that bind to these receptors, PRRT can effectively deliver therapeutic radiation to the tumor site. Studies have demonstrated that PRRT meningioma treatment can be safe, well-tolerated, and effective in controlling disease progression in patients with meningiomas. For instance, research has indicated that PRRT with 111In-Pentetreotide can be a safe and effective option for disease control. Furthermore, new research presented in The Journal of Nuclear Medicine deems PRRT a safe and efficacious alternative for advanced meningiomas.

Despite the therapeutic potential, certain conditions and patient factors can serve as contraindications to PRRT. The Joint EANM/EANO/RANO/SNMMI practice guideline adapts contraindications for PRRT from guidelines for neuroendocrine tumors. While absolute contraindications are not extensively detailed in publicly available summaries, general principles of patient suitability for radiation therapy applyEstrogen Hormone Replacement Therapy in Incidental Meningioma. This includes assessing overall health, renal and hepatic function, and the presence of other severe comorbidities that could compromise a patient's ability to tolerate treatment and its associated side effectsInnovative treatments for meningiomas. Comprehensive patient evaluation by a multidisciplinary team is essential to determine eligibility.

Understanding Potential Contraindications and Side Effects

The investigation into meningioma contraindication to peptides is an ongoing area of research. While PRRT has shown a good safety profile, understanding potential risks is paramount. Some research suggests a potential link between the long-term use of certain progestogen drugs, such as high doses of medroxyprogesterone acetate and cyproterone acetate, and an increased risk of meningioma developmentThe Current Role of Peptide Receptor Radionuclide .... A dose-dependent association between cyproterone acetate and the risk of meningioma has been observed, with studies indicating a higher risk even after discontinuation. Similarly, Depo-Provera use has been associated with meningioma risk. While these findings relate to risk factors for developing meningiomas, they underscore the importance of a thorough medical history, including previous or current use of hormonal medications, when considering any treatment involving peptides.

Other factors that may influence treatment decisions, though not strictly considered absolute contraindications for peptides in PRRT, can include:

* Radiation exposure: Certain familial syndromes and prior exposure to ionizing radiation can increase the risk of developing meningiomas. While this is a risk factor for the disease itself, significant prior radiation to the same treatment area might be a consideration for subsequent therapies.

* Specific Gene Mutations and Familial Syndromes: While research is still evolving, understanding the genetic landscape of meningiomas may reveal specific contraindications in the future.

* Pregnancy and Breastfeeding: As with most radiation therapies, PRRT is contraindicated in pregnant or breastfeeding individuals due to potential harm to the fetus or infant.

The side effects of PRRT can vary but may include fatigue, nausea, myelosuppression (low blood counts), and kidney damage. The use of peptides for meningioma treatment is a complex area that requires careful consideration of individual patient circumstances, potential risks, and the expected benefits of therapy. The development of innovative treatments for meningiomas, including peptide-based therapies, continues to offer hope for patients with challenging diagnoses.Prescribing and Medicines Optimisation Guidance (13) Exploring the latest advancements and consulting with experienced neuro-oncology teams are vital steps in navigating these treatment options and ensuring the best possible outcomes.